A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Summary

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Timeline

Start

2025-11-21

Primary completion

2028-10-18

Completion

2028-10-18

Drugs

Indications